Experimental Cancer Drug Inhibits SARS-CoV-2 Virus from Infecting Cells and Replicating
|
By HospiMedica International staff writers Posted on 22 Sep 2020 |

Illustration
A team of scientists has discovered that an experimental cancer drug called AR-12 inhibits the SARS-CoV-2 virus from infecting cells and replicating.
Scientists from the Virginia Commonwealth University Massey Cancer Center (Richmond, VA, USA) are now taking steps to develop a clinical trial for testing the novel oral treatment. AR-12 has been studied extensively by the scientists as both an anti-cancer and anti-viral drug, showing it to be effective against viruses including Zika, mumps, measles, rubella, chikungunya, RSV, CMV, drug resistant HIV and influenza. Their recent research has demonstrated that AR-12 is highly effective against SARS-CoV-2.
“AR-12 works in a unique way. Unlike any other anti-viral drug, it inhibits cellular chaperones, which are proteins that are required to maintain the right 3D shape of viral proteins. The shape of the virus is critical to its ability to infect and replicate,” said Paul Dent, Ph.D., at Virginia Commonwealth University Massey Cancer Center, who is a also professor in the VCU Department of Biochemistry and Molecular Biology and the Universal Corporation Chair in Cancer Cell Signaling and a member of the Cancer Cell Signaling research program at Massey.
One of the cellular chaperones inhibited by AR-12 is GRP78, which is essential for the reproduction of all viruses. GRP78 acts as a sort of cellular stress sensor and is required for the life cycle of all mammalian viruses.
“AR-12 is an oral therapy that has been well tolerated in a prior clinical trial, so we know that it is safe and tolerable. Most COVID-19 drugs are given intravenously, so this would be a unique therapeutic option and potentially suitable for outpatient therapy, similar to the way one would take an antibiotic,” said Andrew Poklepovic, M.D., medical oncologist, member of the Developmental Therapeutics research program and medical director of the Clinical Trials Office at Massey, who is leading the efforts to translate these exciting findings into a clinical trial.
Poklepovic hopes to begin enrolling patients in early 2021, but several milestones remain. The team must develop the clinical trial protocol, receive approval from the FDA to test AR-12 on COVID-19 patients and manufacture enough of the drug for the trial.
“We are working to submit the required information for FDA approvals, and we are also in discussions with a local pharmaceutical company to manufacture the drug for the trial,” said Sebti, Ph.D., associate director for basic research and member of the Developmental Therapeutics program at VCU Massey Cancer Center, and professor of pharmacology and toxicology at the VCU School of Medicine. “We are hopeful that AR-12 will emerge as a treatment option for patients suffering from COVID-19, ultimately saving lives and contributing to the global pandemic solution.”
Related Links:
Virginia Commonwealth University Massey Cancer Center
Scientists from the Virginia Commonwealth University Massey Cancer Center (Richmond, VA, USA) are now taking steps to develop a clinical trial for testing the novel oral treatment. AR-12 has been studied extensively by the scientists as both an anti-cancer and anti-viral drug, showing it to be effective against viruses including Zika, mumps, measles, rubella, chikungunya, RSV, CMV, drug resistant HIV and influenza. Their recent research has demonstrated that AR-12 is highly effective against SARS-CoV-2.
“AR-12 works in a unique way. Unlike any other anti-viral drug, it inhibits cellular chaperones, which are proteins that are required to maintain the right 3D shape of viral proteins. The shape of the virus is critical to its ability to infect and replicate,” said Paul Dent, Ph.D., at Virginia Commonwealth University Massey Cancer Center, who is a also professor in the VCU Department of Biochemistry and Molecular Biology and the Universal Corporation Chair in Cancer Cell Signaling and a member of the Cancer Cell Signaling research program at Massey.
One of the cellular chaperones inhibited by AR-12 is GRP78, which is essential for the reproduction of all viruses. GRP78 acts as a sort of cellular stress sensor and is required for the life cycle of all mammalian viruses.
“AR-12 is an oral therapy that has been well tolerated in a prior clinical trial, so we know that it is safe and tolerable. Most COVID-19 drugs are given intravenously, so this would be a unique therapeutic option and potentially suitable for outpatient therapy, similar to the way one would take an antibiotic,” said Andrew Poklepovic, M.D., medical oncologist, member of the Developmental Therapeutics research program and medical director of the Clinical Trials Office at Massey, who is leading the efforts to translate these exciting findings into a clinical trial.
Poklepovic hopes to begin enrolling patients in early 2021, but several milestones remain. The team must develop the clinical trial protocol, receive approval from the FDA to test AR-12 on COVID-19 patients and manufacture enough of the drug for the trial.
“We are working to submit the required information for FDA approvals, and we are also in discussions with a local pharmaceutical company to manufacture the drug for the trial,” said Sebti, Ph.D., associate director for basic research and member of the Developmental Therapeutics program at VCU Massey Cancer Center, and professor of pharmacology and toxicology at the VCU School of Medicine. “We are hopeful that AR-12 will emerge as a treatment option for patients suffering from COVID-19, ultimately saving lives and contributing to the global pandemic solution.”
Related Links:
Virginia Commonwealth University Massey Cancer Center
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient
Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more
AI Analysis of Smartwatch ECGs May Help Detect Weakened Heart Function
Left ventricular systolic dysfunction (LVSD) occurs when the heart’s main pumping chamber does not contract effectively. The condition can remain asymptomatic for some time but may progress to symptomatic... Read moreCritical Care
view channel
Drone Network Could Speed AED Delivery for Out-of-Hospital Cardiac Arrest
Out-of-hospital cardiac arrest requires rapid emergency intervention, as delays in defibrillation during the critical first minutes after collapse can significantly reduce survival chances.... Read more
AI Models Improve Mortality Risk Prediction After PCI for STEMI
ST-elevation myocardial infarction (STEMI) is a heart attack caused by complete blockage of one or more coronary arteries. More than 2 million people worldwide develop STEMI each year. Percutaneous coronary... Read moreSurgical Techniques
view channel
FDA Authorizes Robotic System for En Bloc Bladder Resection
Bladder cancer frequently recurs, making accurate staging essential for treatment planning. Conventional transurethral resection can fragment tumors, complicating margin assessment and detrusor muscle... Read more
Fluorescence Imaging Reveals Nerves Under Normal Operating-Room Lighting
Preventing unintended nerve injury remains a major concern during surgery, particularly in complex anatomical regions where nerves can be difficult to distinguish from surrounding tissue.... Read more
Programmable Microwave Ablation System Gains CE Mark for Minimally Invasive Tissue Ablation
Hospitals continue to seek minimally invasive approaches that simplify procedural planning and provide controlled energy delivery for tissue ablation. Thermal ablation systems are used across multiple... Read more
Minimally Invasive Balloon Procedure May Redirect Blood Flow During Cardiac Arrest
Out-of-hospital cardiac arrest has a low survival rate, and patients who do not respond to prolonged advanced resuscitation have few remaining treatment options. During cardiopulmonary resuscitation, blood... Read morePatient Care
view channelVirtual Reality Program May Reduce Anxiety Before Pediatric Surgery
Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more
Video-Based Support Helps Older Adults Clarify Kidney Disease Treatment Preferences
Advanced chronic kidney disease (CKD) involves progressive loss of kidney function that can lead to kidney failure and difficult treatment decisions. For older adults, these decisions may include choosing... Read moreMedical Imaging
view channel
Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis
Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more
MRI Test Identifies Candidates for Lower-Dose Radiotherapy in HPV Throat Cancer
Human papillomavirus (HPV)-positive oropharyngeal cancer is a throat cancer linked to HPV infection. Its incidence is rising, and many patients receive high-dose radiotherapy that can cause long-term swallowing... Read moreHealth IT
view channel
Clinical Decision Support Tool Automates CKD Risk Assessment in Primary Care
Chronic kidney disease (CKD) requires timely diagnosis, risk assessment, and coordinated treatment in primary care. Delayed recognition can affect decisions about testing, blood pressure control, cardiovascular... Read more
EHR Alerts Support Dosing, Sedation, and Shock Recognition in Cardiac Care
Electronic health record alerts can add to clinician workload when they are poorly targeted. In critical cardiac care, however, delayed decisions can affect treatment timing, sedation exposure, and escalation... Read morePoint of Care
view channel
Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier
Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more
New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring
Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read moreBusiness
view channel
Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings
Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more








